Markets

PetroFrontier Corp. (TSXV: PFC) announces further delays in filing financial statements. Annual filings are now expected by June 26, 2025 and Q1 filings by July 10, 2025, impacting CEO/CFO trading and an existing cease trade order. The company cites data delays from its limited partnership investment. While providing biweekly updates, PetroFrontier, focused on Alberta heavy oil plays, faces exchange listing risks related to these delays.

Actuate Therapeutics announced positive Phase 2 results for elraglusib in previously untreated metastatic pancreatic cancer. The combination with gemcitabine/nab-paclitaxel significantly improved overall survival to 10.1 months, compared to 7.2 months for the control, with a 37% reduction in death risk. The 12-month survival rate also doubled. Actuate plans to discuss product registration with the FDA.

A Phase 3 trial (PANOVA-3) showed that Tumor Treating Fields (TTFields) therapy combined with gemcitabine and nab-paclitaxel improved overall survival in patients with unresectable, locally advanced pancreatic cancer and reduced pain duration compared to chemotherapy alone. The results are published in the *Journal of Clinical Oncology* and will be presented at ASCO. Novocure plans to submit the data to the FDA for approval.

In an interview, Fuyao Glass Chairman Cao Dewang revealed his ambitious vision for Fuyao University of Technology, aiming to create a globally recognized institution akin to Stanford. He emphasized the project’s importance in building future confidence and expressed immense pressure for its success. Despite skepticism, the university, led by President Wang Shuguo, plans to cultivate doctoral graduates by age 25 and offers personalized learning plans. Cao views the university as a crucial mission to nurture accomplished individuals.

Tempus AI launched its Fuses program to create an AI-powered diagnostic platform for precision medicine. Leveraging its vast, multimodal dataset, the initiative will build models to improve diagnostics, prognostics, and predictions. Fuses aims to translate data insights into clinically validated tests for personalized patient care, including identifying those unlikely to respond to current therapies. The program seeks to transform diagnostics and help match patients with the most effective treatments.

Genentech announced positive overall survival data from the Phase III INAVO120 study, showing that the Itovebi regimen reduced death risk by over 30% in advanced breast cancer patients with PIK3CA mutations. Compared to palbociclib and fulvestrant alone, this Itovebi combination with palbociclib and fulvestrant significantly improved overall survival. The findings will be presented at the 2025 ASCO meeting.

Huawei’s Richard Yu revealed internal struggles behind the HarmonyOS-powered Smart Car initiative at the 2025 Future Automotive Pioneers Conference. He discussed challenges including external policy hurdles and internal misunderstandings. Yu highlighted the evolution of the project and drew parallels to Huawei’s earlier brand-building efforts, expressing optimism that the effort will ultimately succeed and contribute significantly to the Chinese automotive market.

At the 2025 Future Automotive Pioneers Conference, Huawei’s Richard Yu outlined the company’s automotive vision. Key takeaways include Huawei’s strong brand appeal, leading autonomous driving tech, premium AITO brand positioning, and advances in smart cockpits. Yu also emphasized Huawei’s compliance with national standards, cautioned against flawed industry practices, and criticized relying on the lowest performing benchmarks. He highlighted the need for true innovation over hype.

Destination XL Group (DXLG) opened a new DXL store in Boca Raton, Florida, its fifth new store this fiscal year. Catering to Big + Tall menswear, the store offers exclusive designs and various brands. DXL utilizes FiTMAP^SM Sizing Technology for personalized recommendations. This expansion aims to provide a streamlined shopping experience and empower customers to express their personal style through well-fitting apparel.

At the 2025 Future Automotive Pioneers Conference, Huawei’s Richard Yu criticized EV quality control. He claimed some automakers wouldn’t meet Huawei’s standards. Yu stressed that quality is paramount, advocating for consumer safety and urging the industry to avoid setting low standards. He called for innovation to prevent stagnation and challenged deceptive advertising practices.